Acasti Pharma Stock Analysis

Acasti Stock Analysis Notes

About 16.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.49. Some equities with similar Price to Book (P/B) outperform the market in the long run. Acasti Pharma recorded a loss per share of 5.68. The entity had not issued any dividends in recent years. The firm had 1:6 split on the 10th of July 2023. Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. The company was incorporated in 2002 and is headquartered in Laval, Canada. Acasti Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. For more info on Acasti Pharma please contact Janelle DAlvise at 450-687-2262 or go to https://www.acastipharma.com.

Acasti Pharma Investment Alerts

Acasti Pharma Upcoming and Recent Events

Acasti Largest EPS Surprises

View All Earnings Estimates

Acasti Pharma Environmental, Social, and Governance (ESG) Scores

Acasti Stock Institutional Investors

Note, although Acasti Pharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Acasti Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 29.98 M.

Acasti Profitablity

Management Efficiency

Acasti Pharma has return on total asset (ROA) of (0.0792) % which means that it has lost $0.0792 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4805) %, meaning that it created substantial loss on money invested by shareholders. Acasti Pharma's management efficiency ratios could be used to measure how well Acasti Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to gain to 0.25 in 2024, whereas Return On Tangible Assets are likely to drop (1.34) in 2024. Liabilities And Stockholders Equity is likely to gain to about 95.5 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 3.7 M in 2024.

Technical Drivers

As of the 8th of June, Acasti Pharma shows the risk adjusted performance of (0.01), and Mean Deviation of 1.62. Acasti Pharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Acasti Pharma Price Movement Analysis

Acasti Pharma Insider Trading Activities

Acasti Pharma Predictive Daily Indicators

Acasti Pharma Corporate Filings

Acasti Pharma Forecast Models

Acasti Pharma's time-series forecasting models are one of many Acasti Pharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Acasti Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Acasti Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Acasti shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Acasti Pharma. By using and applying Acasti Stock analysis, traders can create a robust methodology for identifying Acasti entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Acasti analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Acasti analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Acasti Pharma stock analysis indicators help investors evaluate how Acasti Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Acasti Pharma shares will generate the highest return on investment. By understating and applying Acasti Pharma stock analysis, traders can identify Acasti Pharma position entry and exit signals to maximize returns.

When running Acasti Pharma's price analysis, check to measure Acasti Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acasti Pharma is operating at the current time. Most of Acasti Pharma's value examination focuses on studying past and present price action to predict the probability of Acasti Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acasti Pharma's price. Additionally, you may evaluate how the addition of Acasti Pharma to your portfolios can decrease your overall portfolio volatility.